1. Lok AS, McMahon BJ. American Association for the Study of Liver Diseases Practice Guidelines. Chronic Hepatitis B. Hepatology 2007;45:507-39. Chronic Hepatitis B: Update 2009
  2. Cooley L, Ayres A, Bartholomeusz A, et al. Prevalence and characterization of lamivudine-resistant hepatitis B virus mutations in HIV-HBV co-infected individuals. AIDS 2003;17:1649-57.
  3. Perrillo R. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 2001;120:1009-22.
  4. Busche M, Laycock M, Mohr B, et al. Failure of serological assays for diagnosis of hepatitis B and C virus infections in patients with advanced HIV. Program Abstract. 8th Conf Retrovir Oppor Infect 2001;8:112 (abstract no. 235).
  5. Iloeje UH, Yang HI, Su J, et al; Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer In HBV (the REVEAL-HBV) Study Group. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006;130:678-86.
  6. Chen CJ, Yang HI, Su J, et al; REVEAL-HBV Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73.
  7. Chung R, Kinm A. HIV / Hepatitis B and C co-infection: pathogenic interactions, natural history and therapy. Antivir Chem Chemother 2001;12:73-91.
  8. Colin J, Cazals-Hatem D, Loriot M, et al. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology 1999;29:1306-10.
  9. Horvath J, Raffanti S. Clinical aspects of the interactions between human immunodeficiency virus and the heterotropic viruses. Clin Infect Dis 1994;18:339-47.
  10. Gatanaga H, Yasuoka A, Kikuchi Y, et al. Influence of prior HIV-1 infection on the development of chronic hepatitis B infection. Eur J Clin Microbiol Infect Dis 1997;19:237-9.
  11. Hyams K. Risks of chronicity following acute hepatitis B virus infection: a review. Clin Infect Dis 1995;20:992-1000.
  12. Richards M, Lucas C, Gust I. Hepatitis in male homosexuals in Melbourne. Med J Aust 1983; 2:474-5.
  13. Bodsworth N, Cooper D, Donovan B. The influence of human immunodeficiency type 1 infection on the development of the hepatitis B carrier state. J Infect Dis 1991;163:1138-40.
  14. Gilson R, Hawkins A, Beecham M, et al. Interactions between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection. AIDS 1997;11:597-606.
  15. Hadler S, Judson F, O’Malley P, et al. Outcome of hepatitis B infection in homosexual men and its relationship to prior human immunodeficiency virus infection. J Infect Dis 1991;163:454-9.
  16. Thio CL, Seaberg EC, Skolasky R Jr, et al; Multicenter AIDS Cohort Study. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002;360:1921-6.
  17. Weber R, Sabin CA, Friis-Møller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006;166:1632-41.
  18. Hoffmann CJ, Seaberg EC, Young S, et al. Hepatitis B and long-term HIV outcomes in co-infected HAART recipients. AIDS 2009;23:1881-9.
  19. Fang J, Wright T, Lau J. Fibrosing cholestatic hepatitis in a patient with human immunodeficiency virus and hepatitis B virus co-infection. Lancet 1993;342:1175.
  20. Scharschmidt B, Held M, Hollander H, et al. Hepatitis B in patients with HIV infection: relationship to AIDS and patient survival. Ann Intern Med 1992;117:837-8.
  21. Solomon R, Van Raden M, Kaslow R, et al. Association of hepatitis B surface antigen and core antibody with acquisition and manifestation of human immunodeficiency virus type 1 (HIV-1). Am J Public Health 1990;80:1475-8.
  22. Sulkowski MS, Thomas D, Chaisson R, et al. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. J Am Med Assoc 2000;283:74-80.
  23. Sulkowski M, Thomas D, Mehta S, et al. Hepatotoxicity associated with nevirapine or efavirenz- containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 2002;35:182-9.
  24. Saves M, Raffi F, Clevenbergh P, et al. Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatocytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients. The APROCO Study Group. Antimicrob Agents Chemother 2000;44:3451-5.
  25. Cahn P, Villacian J, Lazzarin A, et al. Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial. Clin Infect Dis 2006;43:1347-56.
  26. Gathe J, Cooper DA, Farthing C, et al. Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial. Clin Infect Dis 2006;43:1337-46.
  27. Kontorinis N, Dieterich D. Hepatotoxicity of antiretroviral therapy. AIDS Rev 2003;5:36-43.
  28. Hoff J, Bani-Sadr F, Gassin M, et al. Evaluation of chronic hepatitis B virus (HBV) infection in coinfected patients receiving lamivudine as a component of anti-human immunodeficiency virus regimens. Clin Infect Dis 2001;32:963-9.
  29. Carr A, Cooper D. Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor. Lancet 1997;349:995-6.
  30. Proia L, Ngui S, Kaur S, et al. Reactivation of hepatitis B in patients with human immunodeficiency virus infection treated with combination antiretroviral therapy. Am J Med 2000;108:249-51.
  31. Matthews GV, Avihingsanon A, Lewin SR, et al. A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand. Hepatology 2008;48:1062-9.
  32. Manegold C, Hannoun C, Wywiol A, et al. Reactivation of hepatitis B virus replication accompanied by acute hepatitis in patients receiving highly active antiretroviral therapy. Clin Infect Dis 2001;32:144-8.
  33. Liaw Y, Chien R, Yeh C, et al. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999;30:567-72.
  34. Bessesen M, Ives D, Condreay L, et al. Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine. Clin Infect Dis 1999;28:1032-5.
  35. Rockstroh JK, Bhagani S, Benhamou Y, et al; EACS Executive Committee. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C co-infection in HIV-infected adults. HIV Med 2008;9:82-8.
  36. Degos F, Perez P, Roche B, et al; FIBROSTIC study group. Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study). J Hepatol 2010;53:1013-21.
  37. Australasian Society for HIV Medicine. Australian Commentary on the US Department of Health and Human Services (DHHS) Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents (1 May 2014). Available at: (last accessed 10 August 2015).
  38. McMahon MA, Jilek BL, Brennan TP, et al. The HBV drug entecavir - effects on HIV-1 replication and resistance. N Engl J Med 2007;356:2614-21.
  39. Di Biscegli A. Interferon therapy for chronic viral hepatitis. N Engl J Med 1994;330:137-8.
  40. McDonald J, Caruso L, Karayiannis P, et al. Diminished responsiveness of male homosexual chronic hepatitis B virus carriers with HTLV-III antibodies to recombinant alpha-interferon. Hepatology 1987;7:719-23.
  41. Wong D, Cheung A, O’Rourke K, et al. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993;119:312-23.
  42. Marcellin P, Boyer N, Colin J, et al. Recombinant alpha interferon for chronic hepatitis B in anti-HIV positive patients receiving zidovudine. Gut 1993;34 Suppl 2:S106.
  43. Chen DK, Yim C, O’Rourke K, et al Long-term follow-up of a randomized trial of interferon therapy for chronic hepatitis B in a predominately homosexual male population. J Hepatol 1999;30:557-63.
  44. Coates J, Cammack N, Jenkinson H, et al. (-)-2´-deoxy-3´-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro. Antimicrob Agents Chemother 1992;36:733-9.
  45. Doong S, Tsai C, Schinazi R, et al. Inhibition of the replication of hepatitis B virus in vitro by 2´,3´-dideoxy- 3´-thiacytidine and related analogues. Proc Natl Acad Sci USA 1991;88:3495-9.
  46. Benhamou Y, Katlama C, Lunel F, et al. Effects of lamivudine on replication of hepatitis B virus in HIV-infected men. Ann Intern Med 1996;125:705-12.
  47. Dore G, Cooper D, Barrett C, et al. Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-co-infected persons in a randomized,controlled study (CAESAR). The CAESAR Coordinating Committee. J Infect Dis 1999;180:607-13.
  48. Nagai K, Hosaka H, Kubo S, et al. Highly active antiretroviral therapy used to treat concurrent hepatitis and human immunodeficiency virus infections. J Gastroenterol 1999;34:275-81.
  49. Leung N, Lai CL, Chang T, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy. Hepatology 2001;33:1527-32.
  50. Benhamou Y, Bochet M, Thibault V, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus- infected patients. Hepatology 1999;30:1302-6.
  51. Matthews G, Bartholameusz A, Locarnini S, et al. Characteristics of HBV resistance in an international collaborative study of HIV/HBV infected individuals on extended lamivudine therapy. AIDS 2006;20(6):863-7048.
  52. Benhamou Y, Thibault V, Vig P, et al. Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1. J Hepatol 2006;44:62-7.49
  53. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008;359:2442-55.
  54. van Bömmel F, Wünsche T, Mauss S, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 2004 Dec;40:1421-5.
  55. Piketty C, Pellegrin I, Katlama C, et al. Efficacy of tenofovir disoproxil fumarate in hepatitis B virus in HIV-co-infected patients: the TECOVIR Study. San Francisco: CROI; 2004.
  56. Agarwal K, Brunetto M, Seto WK 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection J Hepatol 2018; 68:672-81.
  57. Gallant JE, Daar ES, Raffi F, et al. Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial. Lancet HIV. 2016; 3:e158-65.
  58. Innaimo S, Seifer M, Bisacchi G, et al. Indentifcation of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob Agents Chemother 1997; 41:1444-48.
  59. Yamanaka G, Wilson T, Innaimo S, et al. Metabolic studies on BMS-200475, a new antiviral compound against hepatitis B virus. Antimicrob Agents Chemother 1999;43:190-3.
  60. Lai C, Shouval D, Lok A, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis. N Engl J Med 2006;354:1011-20.
  61. McMahon MA, Jilek BL, Brennan TP, et al. The HBV drug entecavir - effects on HIV-1 replication and resistance. N Engl J Med 2007;356:2614-21.
  62. Sasadeusz J, Audsley J, Mijch A, et al. The anti-HIV activity of entecavir: a multicentre evaluation of lamivudine-experienced and lamivudine-naive patients. AIDS 2008;22:947-55.
  63. Sherman M, Yurdaydin C, Simsek H, et al; AI463026 Benefits of Entecavir for Hepatitis B Liver Disease (BEHoLD) Study Group. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology 2008;48:99-108.
  64. Dusheiko G, Danta M. Telbivudine for the treatment of chronic hepatitis B. Drugs Today (Barc) 2007;43:293-304.